Literature DB >> 15048676

Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome.

Chiung-Nien Chen1, Fon-Jou Hsieh, Yung-Ming Cheng, Po-Huang Lee, King-Jen Chang.   

Abstract

BACKGROUND AND OBJECTIVES: Overexpression of eIF4E can result in oncogenic transformation and uncontrolled growth of mammalian cells, presumably by facilitating the expression of growth-control gene products, which are normally translationally repressed. Overexpression of eIF4E was present in human breast carcinoma and human head and neck squamous cell carcinoma, and may be of prognostic value in breast carcinomas. In order to elucidate the clinical significance of eIF4E expression, this study was conducted to quantify expression of eIF4E in human gastric cancer tissue and correlate them with clinicopathological factors and patient survival.
METHODS: Specimens from sixty-nine patients with gastric adenocarcinoma were analyzed and eIF4E overexpression was quantified by Western blot analysis. Quantification of eIF4E levels in cancer was expressed relative to controls from non-tumorous mucosa of the same patients. Confirmation of eIF4E overexpression at the cellular level was performed using immunohistochemical staining. The association of clinicopathologic factors and survival with eIF4E expression was analyzed.
RESULTS: In non-tumorous parts of specimens, overexpression of eIF4E was always present in gastric glands but not in gastric pits lining mucosa, and it was also expressed in the areas of intestinal metaplasia and dysplasia. In the 69 specimens, the mean eIF4E expression was 5.77 +/- 8.55-fold (mean +/- standard deviation), ranged from from 0.1-fold to 38-fold. The degree of eIF4E expression appeared to be independent of invasion depth of tumor, lymph node metastasis, Lauren classification, Borrmann types, and Helicobacter pylori infection. Marked overexpression of eIF4E (more than seven-fold) was correlated with tumor vascular invasion (P = 0.046, Fisher exact-test). The survival rate of the patients with underexpression or mild overexpression of eIF4E (less than sevenfold) was significantly higher than that with marked eIF4E overexpression (more than sevenfold) (P = 0.01734, log rank test).
CONCLUSIONS: Marked eIF4E overexpression in gastric cancer was found to be associated with vascular invasion. The prognosis for gastric cancer patients with marked overexpression of eIF4E was worse than those with underexpression. It may serve as an additional prognostic and therapeutic factor in gastric cancer, and deserves further investigation. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048676     DOI: 10.1002/jso.20037

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  21 in total

Review 1.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

2.  The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.

Authors:  Oscar Tapia; Ismael Riquelme; Pamela Leal; Alejandra Sandoval; Susana Aedo; Helga Weber; Pablo Letelier; Enrique Bellolio; Miguel Villaseca; Patricia Garcia; Juan Carlos Roa
Journal:  Virchows Arch       Date:  2014-05-21       Impact factor: 4.064

Review 3.  Targeting the translation machinery in cancer.

Authors:  Mamatha Bhat; Nathaniel Robichaud; Laura Hulea; Nahum Sonenberg; Jerry Pelletier; Ivan Topisirovic
Journal:  Nat Rev Drug Discov       Date:  2015-03-06       Impact factor: 84.694

4.  Translation initiation factor eIF4E is a target for tumor cell radiosensitization.

Authors:  Thomas J Hayman; Eli S Williams; Muhammad Jamal; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Cancer Res       Date:  2012-03-07       Impact factor: 12.701

5.  eIF4EBP3 was downregulated by methylation and acted as a tumor suppressor by targeting eIF4E/β-catenin in gastric cancer.

Authors:  Shuting Zhai; Shuang Lin; Zhongjie Lin; Junjie Xu; Tong Ji; Ke Chen; Ke Wu; Hui Liu; Hanning Ying; Weiqiang Fei; Jin Wang; Guoxiang Fu; Yifan Wang; Xiaotong Hu; Xiujun Cai
Journal:  Gastric Cancer       Date:  2019-12-18       Impact factor: 7.370

Review 6.  Updated overview of current biomarkers in head and neck carcinoma.

Authors:  Kiran Dahiya; Rakesh Dhankhar
Journal:  World J Methodol       Date:  2016-03-26

7.  EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma.

Authors:  Mengyan Wu; Yingxia Liu; Xiaoqing Di; Haixian Kang; Hua Zeng; Yi Zhao; Kangrong Cai; Tianyun Pang; Sen Wang; Yunhong Yao; Xinrong Hu
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

8.  The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.

Authors:  Ismael Riquelme; Oscar Tapia; Jaime A Espinoza; Pamela Leal; Kurt Buchegger; Alejandra Sandoval; Carolina Bizama; Juan Carlos Araya; Richard M Peek; Juan Carlos Roa
Journal:  Pathol Oncol Res       Date:  2016-05-07       Impact factor: 3.201

9.  Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.

Authors:  S C Thumma; B A Jacobson; M R Patel; B W Konicek; M J Franklin; J Jay-Dixon; A Sadiq; A De; J R Graff; R A Kratzke
Journal:  Cancer Gene Ther       Date:  2015-07-31       Impact factor: 5.987

Review 10.  Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.

Authors:  Bing-Hua Jiang; Ling-Zhi Liu
Journal:  Drug Resist Updat       Date:  2008-04-28       Impact factor: 18.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.